article thumbnail

Anthem Caps Coverage Of Biogen Spine Drug Despite Wide FDA Approval

Xconomy

One of the nation’s major health insurers has placed limitations on access to the first-ever approved drug for the rare spinal muscular atrophy, validating patient fears that the high price tag of the drug, nusinersen (Spinraza), might make it hard for some with the disease to get treatment.

Anthem 40
article thumbnail

Insurer UHC Will Cover Biogen Spine Drug, But With Limits And Proof

Xconomy

health insurer, UnitedHealthCare, has said it would cover the first-ever approved drug for the rare disease spinal muscular atrophy, a closely watched bellwether in the national debate over drug prices. Another major U.S.

Anthem 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

This Week in VC with Farb Nivi, Founder of Grockit

Both Sides of the Table

I don’t do advertising on my blog, but I thought it was worth mentioning Ryan in particular because he has an alternate model for doing a startup. Pricing engine helps publishers ascertain ad inventory pricing by analyzing ad transaction data from the market/exchanges. They sponsor TWiVC. MetaMarkets. Hello, Chair.

article thumbnail

This Week in VC with Om Malik & Paul Jozefak

Both Sides of the Table

An investment doesn’t guarantee your product will suddenly be on the investor’s price sheet. Diverse search results include stream updates, blog posts, news articles, photos, videos (versus Twitter/FaceBook1 only). Current round: $5.0mm in Series A by NEA and Anthem Venture Partners. Real-time search engine.

article thumbnail

Families Fret As Insurers Mull Biogen’s $750K Spine Disease Drug

Xconomy

But just after Christmas, she saw the price. More than a decade after his diagnosis, Mikhail only has the strength to take a few steps on his own. With the approval, Memedovich finally had hope. Cambridge, MA-based Biogen (NASDAQ: BIIB ), the drug’s. Read more » Reprints | Share:

Pricing 78
article thumbnail

Bio Roundup: Travel Ban, Pharma in D.C., Biogen Splits, PCSK9 Wins

Xconomy

At the same time, a handful of the industry’s top CEO’s flew to Washington for a meeting with the President, who promised to speed the drug approval process, lower drug prices, and overhaul the FDA. Meanwhile, the future of the Affordable Care Act remains undecided, and Tom Price’s controversial candidacy for the top healthcare.

Pricing 40
article thumbnail

“Our Son’s Fate”: Parents Fighting for Kids’ Spine Drug Eye New Data

Xconomy

Melissa Marotta pulled no punches to get her three-year-old son C.J., who has the genetic disease spinal muscular atrophy, access to nusinersen (Spinraza), the first approved drug for his condition.

Anthem 73